Table 1.
Clinicopathologic characteristics by constructed molecular subtype
| Characteristic | HR+/HER2- (n = 309) |
HR+/HER2+ (n = 51) |
HR-/HER2+ (n = 42) |
HR-/HER2- (n = 193) |
* P-value |
|---|---|---|---|---|---|
| Age, years | 0.28 | ||||
| Median (range) |
51 (29 to 83) |
51 (27 to 72) |
49 (26 to 65) |
49 (27 to 76) |
|
| Clinical T-stage | 0.09 | ||||
| T0 | 1 (0.3%) | 0 | 0 | 0 | |
| T1 | 65 (21%) | 5 (10%) | 6 (14%) | 19 (10%) | |
| T2 | 207 (67%) | 36 (70%) | 33 (79%) | 140 (73%) | |
| T3 | 25 (8%) | 5 (10%) | 3 (7%) | 22 (11%) | |
| T4 | 10 (3%) | 5 (10%) | 0 | 12 (6%) | |
| Tx | 1 (0.3%) | 0 | 0 | 0 | |
| Clinical N-stage | 0.03 | ||||
| N0 | 167 (54%) | 29 (57%) | 11 (26%) | 101 (52%) | |
| N1 | 110 (36%) | 15 (29%) | 23 (55%) | 62 (32%) | |
| N2 | 12 (4%) | 1 (2%) | 4 (9.5%) | 9 (5%) | |
| N3 | 20 (6%) | 6 (12%) | 4 (9.5%) | 21 (11%) | |
| Clinical stage | 0.18 | ||||
| I | 26 (8%) | 4 (8%) | 2 (5%) | 8 (4%) | |
| II | 234 (76%) | 35 (69%) | 30 (71%) | 137 (71%) | |
| II | 50 (16%) | 12 (23%) | 10 (24%) | 48 (25%) | |
| Nuclear grade | < 0.001 | ||||
| 1 | 15 (5%) | 1 (2%) | 0 | 0 | |
| 2 | 144 (47%) | 14 (28%) | 3 (7%) | 21 (11%) | |
| 3 | 149 (48%) | 36 (70%) | 39 (93%) | 172 (89%) | |
| Unknown | 1 (0.3%) | 0 | 0 | 0 | |
| LVI | 0.47 | ||||
| Yes | 55 (18%) | 5 (10%) | 7 (17%) | 28 (15%) | |
| No | 254 (82%) | 46 (90%) | 35 (83%) | 165 (85%) | |
| Pathologic tumor size, cm | < 0.001 | ||||
| Median (range) |
1.5 (0 to 9) |
1.1 (0 to 4) |
0.1 (0 to 8) |
0.3 (0 to 5.5) |
|
| Number positive lymph nodes | |||||
| 0 | 152 (49%) | 34 (67%) | 27 (64%) | 149 (77%) | < 0.001 |
| 1-3 | 103 (33%) | 9 (18%) | 11 (26%) | 32 (17%) | |
| ≥ 4 | 53 (17%) | 6 (12%) | 4 (10%) | 12 (6%) | |
| Unknown | 1 (0.3%) | 2 (3%) | 0 | 0 | |
| Number lymph nodes sampled | 0.04 | ||||
| Median (range) |
12 (0 to 40) |
5 (0 to 27) |
13 (1 to 37) |
9 (1 to 30) |
|
| pCR | < 0.001 | ||||
| Yes | 27 (9%) | 9 (18%) | 15 (36%) | 73 (38%) | |
| No | 282 (91%) | 42 (18%) | 27 (64%) | 120 (62%) | |
*The Kruskal-Wallis test was used for age (continuous variable). All other P-values were determined using the χ2 test for equality of distributions. LVI, lymphovascular invasion; pCR, pathologic complete response